Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
Amylyx stock slips 6% after phase 2 rare disease data drop
Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome
Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024
Based on topline results from the Phase 3 PHOENIX trial of AMX0035 in ALS, Amylyx has started a process with the FDA and Health Canada of voluntarily discontinuing the marketing authorizations for RELYVRIO/ALBRIOZA
Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO®/ALBRIOZA™ from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy
Shareholders of Amylyx Pharmaceuticals Should Contact The Gross Law Firm
Amylyx Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
Amylyx Pharmaceuticals Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS
Amylyx Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035